Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Updated RAMP 201 Data to Support NDA Submission for Avutometinib/Defactinib Combo in Recurrent KRAS+ Ovarian Cancer

October 17th 2024

Updated RAMP 201 data will support an NDA submission to the FDA for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

Dr Lorusso on Key Takeaways About Relacorilant Combination Treatment in Ovarian Cancer

October 16th 2024

Domenica Lorusso, MD, PhD, discusses the selective glucocorticoid receptor modulator relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Dr Lorusso on Relacorilant Plus Nab-Paclitaxel in Recurrent, Platinum-Resistant Ovarian Cancer

October 11th 2024

Domenica Lorusso, MD, PhD, discusses findings from a trial evaluating relacorilant plus nab-paclitaxel in recurrent, platinum-resistant ovarian cancer.

Gotistobart Plus Pembrolizumab Shows Activity in Platinum-Resistant Ovarian Cancer

October 7th 2024

Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.

FDA Grants Fast Track Status to VLS-1488 for Platinum-Resistant High-Grade Serous Ovarian Cancer

October 3rd 2024

The KIF18A inhibitor VLS-1488 has received fast track designation from the FDA for platinum-resistant high-grade serous ovarian cancer.

Mirvetuximab Soravtansine Gains Traction in Heavily Pretreated FRα+ Platinum-Sensitive Ovarian Cancer

September 29th 2024

Angeles Secord, MD, MHSc, discusses data with mirvetuximab soravtansine in heavily pretreated FRα-positive recurrent, platinum-sensitive ovarian cancer.

Dr Lorusso on the Use of Selective Glucocorticoid Receptor Modulators in Recurrent Ovarian Cancer

September 27th 2024

Domenica Lorusso, MD, PhD, discusses the rationale for investigating relacorilant combined with nab-paclitaxel in recurrent, platinum-resistant ovarian cancer.

Dr Chambers on Access, Toxicities, and Long-term Considerations for PARP Inhibitors in Ovarian Cancer

September 23rd 2024

Laura J. Chambers, DO, discusses challenges patients with ovarian cancer face in accessing PARP inhibitor treatment.

CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer

September 20th 2024

The EMA’s CHMP has recommended the marketing authorization of mirvetuximab soravtansine for FRα-positive, platinum-resistant epithelial ovarian cancer.

Dr Secord on the Safety of Mirvetuximab in Recurrent Platinum-Sensitive Ovarian Cancer

September 19th 2024

Angeles A. Secord, MD, MHSc, discusses safety findings from the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive ovarian cancer.

Dato-DXd Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian and Endometrial Cancers

September 18th 2024

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

FDA Lifts Partial Clinical Hold on Trials Evaluating Azenosertib in Advanced Solid Tumors

September 16th 2024

The FDA has lifted the partial clinical hold previously placed on studies evaluating azenosertib in advanced solid tumors.

TORL-1-23 Is Tolerable, Active in Heavily Pretreated CLDN6+ Advanced Ovarian Cancer, Other Solid Tumors

September 15th 2024

TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.

Dr Secord on Mirvetuximab Soravtansine in Platinum-Sensitive, FRα-High Ovarian Cancer

September 15th 2024

Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

September 15th 2024

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Cannavale on the Importance of Assessing Comorbidities and Remission Rates in Ovarian Cancer

September 13th 2024

Kimberly Cannavale, MPH, discusses the clinical implications of a study on the impact of pre-existing comorbidities on remission rates in ovarian cancer.

Cannavale on the Effect of Comorbidity on Remission Rates in Epithelial Ovarian Cancer

September 11th 2024

Kimberly Cannavale, MPH, discusses the rationale for investigating the effect of pre-existing comorbidities on remission rates in ovarian cancer.

Dr Asare on the Elevated Risk of Secondary Leukemias in PARP Inhibitors in Gynecologic Cancers

September 10th 2024

Amma Asare, MD, PhD, discusses the elevated risk of therapy-related myeloid neoplasms or secondary leukemias in gynecologic cancers after a PARP inhibitor.

FDA Grants Orphan Drug Designation to NXP800 for ARID1a-Deficient Ovarian Cancers

August 29th 2024

NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

Charlson Comorbidities Associated With Lower Likelihood of CR in Epithelial Ovarian Cancer

August 28th 2024

Kimberly Cannavale, MPH, discusses a study of the association between Charlson comorbidity index and complete remission in patients with ovarian cancer.